INX-315 for advanced cancers with a specific gene change
Treatments studied
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that can’t be fully removed or has spread, and it has grown after standard treatment
- Your tumor must have a specific CCNE-1 amplification gene change (for certain breast, ovarian, or other solid tumors)
- You were treated with a CDK4/6 inhibitor before (for the breast cancer group) and your cancer still progressed
- You have at least one measurable spot on scans that has not been treated with radiation before
- Your general health is good enough for study treatment (ECOG 0 or 1)
- Your bloodwork and organ function are adequate (including certain minimum blood counts and kidney/liver test levels)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.